Who Paid My Doc
Michael Guy
Gynecologic Oncology Kettering, OH Medical Doctor
NPI 1174773287 CMS profile 1310590
3700 Southern Blvd Ste 201, Kettering, OH 45429
General payments
$4,708
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$600,567
Through program year 2025, Michael Guy of Kettering, OH is reported in the CMS Open Payments database as having received $4,708 across 34 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $600,567 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 70th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,491 | 9 | |
| 2024 | General | $121 | 1 | |
| 2023 | General | $552 | 7 | |
| 2022 | General | $1,369 | 9 | |
| 2020 | General | $73 | 2 | |
| 2019 | General | $1,102 | 6 |
Beside peers
- Michael Guy
- Gynecologic Oncology median
- Middle half of Gynecologic Oncology
- National median
In program year 2025, general payments to Michael Guy were reported at $1,491. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.
Show as a table
| Year | Michael Guy | Gynecologic Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,102 | $287 | $113–$1,548 | $163 |
| 2020 | $73 | $223 | $59–$2,164 | $114 |
| 2021 | $0 | $193 | $68–$1,139 | $132 |
| 2022 | $1,369 | $252 | $90–$1,151 | $149 |
| 2023 | $552 | $281 | $102–$1,419 | $160 |
| 2024 | $121 | $308 | $108–$1,502 | $164 |
| 2025 | $1,491 | $305 | $111–$1,499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 9 drugsPart D claims
258
Drug cost
$1,079,526
Branded share of claims
36.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Lynparza Olaparib | Brand | 41 | $583,902 | |
| Zejula Niraparib Tosylate | Brand | 19 | $357,258 | |
| Everolimus | Generic | 20 | $132,343 | |
| Ondansetron Hcl | Generic | 41 | $3,854 | |
| Prochlorperazine Maleate | Generic | 31 | $812 | |
| Dexamethasone | Generic | 33 | $564 | |
| Olanzapine | Generic | 39 | $398 | |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | Brand | 23 | $263 | |
| Ondansetron Odt Ondansetron | Brand | 11 | $132 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$54,302
Medicare patients
132
Services billed
370
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 54% | |
| Arthritis | 49% | |
| Depression | 32% | |
| Chronic kidney disease | 27% | |
| Diabetes | 23% | |
| Ischemic heart disease | 23% | |
| Heart failure | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
34 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Gynecologic Oncology in Ohio
David Omalley
Gynecologic Oncology · Hilliard, OH
Thomas Herzog
Gynecologic Oncology · Cincinnati, OH
Floortje Backes
Gynecologic Oncology · Hilliard, OH
Adam Walter
Gynecologic Oncology · Sylvania, OH
Amanda Jackson
Gynecologic Oncology · Cincinnati, OH
Amelia Jernigan
Gynecologic Oncology · Cleveland, OH
Related records
Gynecologic Oncology in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Gynecologic Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.